Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept
Open Access
- 1 August 2012
- journal article
- Published by Taylor & Francis Ltd in Patient Preference and Adherence
- Vol. 6, 589-596
- https://doi.org/10.2147/PPA.S23786
Abstract
Major advances in drug development have led to the introduction of biologic disease-modifying drugs for the treatment of rheumatoid arthritis, which has resulted in unprecedented improvement in outcomes for many patients. These agents have been found to be effective in reducing clinical signs and symptoms, improving radiological damage, quality of life, and functionality, and have also been found to have an acceptable safety profile. Despite this, drug adherence is unknown, which has huge health care and health-economic implications. Local and national guidelines exist for the use of biologics; however, its varied use is widespread. Although this may in part reflect differences in prescribing behavior, patient preference plays a key role. In this review we will explore the factors that contribute to patient preference for, and adherence to, biologic therapy for rheumatoid arthritis with emphasis on the subcutaneous preparation of abatacept, a T-cell costimulatory molecule blocker. Overall, subcutaneous administration is preferred by patients and this may well improve drug adherence.Keywords
This publication has 36 references indexed in Scilit:
- Subcutaneous abatacept versus intravenous abatacept: A phase IIIb noninferiority study in patients with an inadequate response to methotrexateArthritis & Rheumatism, 2011
- Evaluation of abatacept administered subcutaneously in adults with active rheumatoid arthritis: impact of withdrawal and reintroduction on immunogenicity, efficacy and safety (phase Iiib ALLOW study)Annals Of The Rheumatic Diseases, 2011
- Evaluation of performance, safety, subject acceptance, and compliance of a disposable autoinjector for subcutaneous injections in healthy volunteersPatient Preference and Adherence, 2010
- Adherence to Disease-Modifying Antirheumatic Drugs in Patients With Rheumatoid ArthritisOrthopaedic Nursing, 2010
- Primary Medication Non-Adherence: Analysis of 195,930 Electronic PrescriptionsJournal of General Internal Medicine, 2010
- Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)Annals Of The Rheumatic Diseases, 2009
- Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factorsAnnals Of The Rheumatic Diseases, 2009
- Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexateAnnals Of The Rheumatic Diseases, 2008
- Mitogen activated protein kinase inhibitors: where are we now and where are we going?Annals Of The Rheumatic Diseases, 2006
- Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trialAnnals Of The Rheumatic Diseases, 2006